Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab during Boston Keratoprosthesis Implantation
NCT06926478Phase 1Not yet recruiting
- Sponsor
- Massachusetts Eye and Ear
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adalimumab in Graft failure, ocular cicatricial pemphigoid (OCP), Stevens-Johnson syndrome (SJS) and 1 more, sponsored by Massachusetts Eye and Ear. Primary endpoint: Evaluation of Treatment Related Adverse Events at 30 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Graft failureocular cicatricial pemphigoid (OCP)Stevens-Johnson syndrome (SJS)corneal opacity
Beyond the preview
Go deeper on NCT06926478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926478.